Integration of CBX and Technical Assistance Internalization November 3, 2025 1 Disclaimer and Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of applicable securities laws with respect to the proposed internalization of the Technical Assistance Agreement ("TAA") and the integration of Cross Border Xpress ("CBX") into Grupo Aeroportuario del Pacífico, S.A.B. de C.V. ("GAP," and together with the entities involved in the related mergers and transacti ...

Group 1 - The article does not provide any specific content related to a company or industry [1]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Data and Key Metrics Changes - Vertex Pharmaceuticals reported Q3 2025 revenue of $3,080,000,000, reflecting an 11% year-over-year increase, with a 15% growth in the CF segment driven by ongoing patient demand and favorable net pricing [5][40] - Non-GAAP net income for Q3 2025 was $1,240,000,000, up from $1,140,000,000 in Q3 2024, resulting in non-GAAP earnings per share of $4.80, a 10% increase compared to $4.38 in the previous year [42][43] - The company ended the quarter with $12,000,000,000 in cash and investments after repurchasing over 2,700,000 shares [43] Business Line Data and Key Metrics Changes - The CF franchise experienced strong double-digit growth, with the launch of ElefTrex contributing significantly to revenue, generating close to $505,000,000 in sales since its launch [24][56] - KASJEVY revenue for Q3 2025 was $17,000,000, while GERNAVIX contributed $20,000,000, indicating a growing revenue base from new product launches [41] - The renal medicine portfolio is expanding, with multiple programs in pivotal development, including VX407 for ADPKD and povitacicept for IGAN [13][20] Market Data and Key Metrics Changes - The company is seeing increased uptake of ElefTrex in both the U.S. and Europe, with nearly ten times as many newly eligible patients in Europe compared to the U.S. [26][28] - KASJEVY is gaining traction globally, with significant progress in securing access and reimbursement in various regions, including Italy [29][30] - GERNAVIX is being adopted across a wide range of pain settings, with over 300,000 prescriptions filled as of mid-October [37] Company Strategy and Development Direction - Vertex is diversifying its revenue base by expanding its product offerings and geographic reach, particularly in CF and renal diseases [5][12] - The company aims to achieve its long-standing goals in CF by developing medicines that treat a broader range of mutations and patient populations [6][10] - The renal medicine portfolio is positioned as a significant growth driver, with plans to commercialize PoV in IGAN and other serious kidney diseases [38][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing growth of the CF franchise and the potential of new products like ElefTrex and GERNAVIX to drive future revenue [5][22] - The company anticipates continued growth from its CF medicines and expects to achieve over $100,000,000 in KASJEVY revenue for the year [45][46] - Management highlighted the importance of securing broad payer coverage and expanding access to new therapies as key priorities moving forward [32][66] Other Important Information - Vertex has seven commercialized medicines and five programs in Phase III development, indicating a robust pipeline [22] - The company is actively working on securing reimbursement and expanding access for GERNAVIX, with ongoing negotiations with payers [33][66] - Vertex has received breakthrough therapy designation for povitacicept, allowing for a rolling review of its BLA submission [18][82] Q&A Session Summary Question: Status update on ElefTrex and patient switching - Management reported that the majority of newly eligible patients in the U.S. have started on ElefTrex, with strong uptake in countries with access [55][56] Question: Differentiation of PoV data set - Management emphasized the importance of the dual mechanism of action of PoV and its potential to address unmet needs in IGAN [57][59] Question: Current priorities for capital allocation - The company reiterated its focus on reinvesting in the business for innovation and growth, with share buybacks as a secondary priority [72][73] Question: Competitive profile of PoV - Management highlighted the advantages of PoV's auto-injector and monthly dosing, which are expected to improve patient adherence and satisfaction [76][78] Question: Update on the No Pain Act - Management noted that the final list for the No Pain Act has been delayed due to a government shutdown, but they continue to advocate for GERNAVIX's inclusion [85] Question: Coverage details for GERNAVIX - Of the 170,000,000 lives with access to GERNAVIX, 113,000,000 have unrestricted access, with ongoing progress in securing coverage with major PBMs [94]

Core Insights - Howmet Aerospace Inc. (HWM) has a market capitalization of $83 billion and is a prominent provider of advanced engineered solutions for the aerospace and transportation sectors [1] Performance Overview - HWM shares have outperformed the broader market, surging 103.6% over the past 52 weeks compared to a 17.7% increase in the S&P 500 Index [2] - Year-to-date, HWM shares are up 88.3%, while the S&P 500 has gained 16.3% [2] - HWM has also outpaced the SPDR S&P Aerospace & Defense ETF, which returned 56.9% over the past year [3] Financial Results - In Q3 2025, HWM reported an EPS of $0.95 and revenue of $2.09 billion, exceeding expectations [4] - For the fiscal year ending December 2025, analysts project a 37.2% year-over-year growth in EPS to $3.69 [5] - The company has consistently surpassed consensus estimates in the last four quarters [5] Analyst Ratings and Price Targets - The consensus rating among 21 analysts is a "Strong Buy," with 16 "Strong Buy" ratings, one "Moderate Buy," and four "Holds" [5] - RBC Capital analyst Ken Herbert raised the price target for HWM to $235, maintaining an "Outperform" rating [7] - The mean price target of $211.88 indicates a 2.9% premium to current price levels, while the highest target of $225 suggests a potential upside of 9.2% [7]

ORLADEYO Performance and Outlook - ORLADEYO revenue continues strong growth, with a 37% year-over-year increase in Q3 2025[15] - The FY25 guidance range for ORLADEYO revenue has been raised to $590-600 million[17] - Market research reaffirms a strong outlook for ORLADEYO, with an estimated patient LTP share of 24% in 2034[19] - BioCryst anticipates a sustainable $1 billion peak revenue opportunity for ORLADEYO, with a contribution margin exceeding 80%[14] Astria Acquisition and HAE Portfolio Expansion - BioCryst is set to acquire Astria for approximately $700 million TEV, aiming to strengthen its presence in the HAE market[30] - The acquisition is expected to transform BioCryst's revenue profile, projecting a 10+ year double-digit portfolio CAGR[30] - Post-transaction, BioCryst anticipates maintaining profitability (non-GAAP) and positive cash flow[31] - By 2029, the company expects a cash balance of over $1 billion, providing flexibility for future growth opportunities[32] Pipeline Development - Navenibart presents an opportunity to target 5,000+ patients in the US[34] - BCX17725, a targeted KLK5 inhibitor, is under development for Netherton syndrome, with initial Phase 1 data expected by the end of Q1 2026[59]

Core Viewpoint - S&P Global has demonstrated strong financial performance in Q3 2025, with significant growth in earnings and revenue, despite a recent decline in stock price compared to the broader market. Financial Performance - Adjusted earnings per share (EPS) for Q3 2025 reached $4.73, marking a 21.6% increase year-over-year and exceeding the Zacks Consensus Estimate by 7.5% [2][6] - Revenue for the quarter rose by 8.8% to $3.9 billion, surpassing expectations by 1.4%, driven by a 12% increase in the Ratings segment [3][6] Stock Performance - Despite strong financial results, S&P Global's stock has declined by 5.2% over the past six months, contrasting with a 25.2% increase in the Zacks S&P 500 Composite [4] - The current stock price is $489.67, reflecting a decrease of approximately 0.39% or $1.90, with trading between $485.57 and $498 on the day [4] Market Position - S&P Global's market capitalization is approximately $149.5 billion, with a trading volume of 1,033,254 shares on the NYSE [5] - The stock has experienced volatility over the past year, reaching a high of $579.05 and a low of $427.14 [5] Analyst Rating - Evercore ISI reaffirmed its "Outperform" rating for S&P Global, increasing the price target from $619 to $629 [1][6]

Core Insights - AMTD Digital (HKD) experienced a significant stock surge, with shares tripling after reporting a more than 10x year-over-year revenue increase to $73.2 million for the six months ending April 30 [1][2] - The company's chairman emphasized a commitment to delivering long-term value to shareholders [1] Revenue Growth - The remarkable 1,085% revenue increase was primarily attributed to the acquisition of The General Essentials Group (TGE), a media and lifestyle conglomerate purchased in October 2024 [2] - TGE's integration has diversified AMTD's revenue streams, enhancing its position as a digital platform [2][3] Segment Contributions - TGE has significantly contributed to AMTD's media, entertainment, and hospitality segments, including areas such as fashion advertising, luxury publishing, and VIP services [3] Stock Performance and Risks - Despite the impressive revenue growth, the company faces challenges with cost management, as evidenced by a 52% year-over-year decline in earnings per share (EPS) to $0.22 [4] - The stock remains under $5, categorizing it as a penny stock, which is often associated with volatility and speculative trading [5] - The absence of Wall Street coverage raises concerns about institutional interest and overall visibility for investors [6][7]

Financial Performance & Guidance - Emerald is on track to achieve full-year objectives, delivering a 133% year-over-year growth in Revenue and a 324% year-over-year growth in Adjusted EBITDA year-to-date 2025[12] - For Q3 2025, Revenue grew by 67% and Adjusted EBITDA grew by 24%[12] - Full Year 2025 revenue guidance is updated to a range of $460-$465 million, and Adjusted EBITDA guidance is $1225 - $1275 million, reflecting the acquisition of Generis[12, 14, 17] Organic Revenue Analysis - Year-to-date 2025, reported Organic Revenue growth was 10% from the prior year period[12] - Without recent acquisitions, year-to-date Organic Revenue growth would have been 43%[12] - Reported Organic Revenue declined by 68% in Q3 2025; without recent acquisitions, the decline would have been 29%[12] Capital Allocation - The company repurchased 116,094 shares of common stock for $05 million at an average price of $487 per share in Q3 2025[12] - The Board of Directors declared a dividend of $0015 per share for the quarter ending December 31, 2025[12] - The company has bought back a total of 170 million shares of common stock for an aggregate of $700 million since the restart of the share repurchase program in 2021 through September 30, 2025[42] Market Position & Strategy - Emerald is the largest US-based B2B events platform, diversified across end markets, with Connections representing approximately 90% of revenue[18, 19] - B2B US Marketing spend for events and sponsorships is expected to grow by a CAGR of +7% through 2030[29] - The company has completed and integrated over 30 acquisitions over the last decade, deploying approximately $10 billion in capital[39]